Innate PharmaIPHA -3.42%39 Cash Ratio is 0.94 as of Dec. 2025, which is 55% below its 10-year median of 2.07. GuruFocus rates IPHA with a GF Score™ of 39/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,384 Biotechnology companies, Innate Pharma ranks worse than 74.42% on this metric.
Innate Pharma has a Cash Ratio of 0.94. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Innate Pharma's Cash Ratio or its related term are showing as below:
IPHA'
s Cash Ratio Range Over the Past 10 Years
Min: 0.85 Med: 2.07 Max: 3.33
Current: 0.94
During the past 13 years, Innate Pharma's highest Cash Ratio was 3.33. The lowest was 0.85. And the median was 2.07.
IPHA's Cash Ratio is ranked worse than 74.42% of 1384
companies
in the Biotechnology industry
Industry Median: 2.955
vs IPHA: 0.94
Innate Pharma (NAS:IPHA) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Innate Pharma Cash Ratio Related Terms
Innate Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innate Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Cash Ratio of 0.94 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Innate Pharma and its competitors. This is 55% below median its historical median of 2.07. Over the past decade, Innate Pharma's Cash Ratio has ranged from 0.85 to 3.33. According to the industry distribution chart, Innate Pharma ranks #1030 out of 1384 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Innate Pharma's Cash Ratio too high?
Innate Pharma's current Cash Ratio of 0.94 is 55% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 3.33. The Biotechnology industry median Cash Ratio is 2.96. Innate Pharma's value of 0.94 is 68.2% below this industry median. Based on the distribution chart, Innate Pharma ranks #1030 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innate Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #1030 out of 1384 companies for Cash Ratio. This places Innate Pharma in the lower half of its industry. The industry median Cash Ratio is 2.96. Innate Pharma's value of 0.94 is 68.2% below this benchmark. Historically, Innate Pharma's own Cash Ratio has ranged from 0.85 to 3.33 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 2.96, Innate Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Cash Ratio of 0.94 is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Cash Ratio is 0.94, which is 55% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.84 — trading 1046.9% above its estimated fair value. The current Cash Ratio is 0.94, which is 55% below median its 10-year median of 2.07 and 68.2% below the Biotechnology industry median of 2.96. Innate Pharma's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Cash Ratio is 0.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.84 is trading 1046.9% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Cash Ratio: 0.94 (55% below median its 10-year median of 2.07)
GF Value™: $0.16 vs. price of $1.84 (1046.9% above fair value)
Industry Position: 68.2% below the Biotechnology median (#1030 of 1384)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
39GF Score
Get the complete analysis for IPHA
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
